Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Greenlights Soliris for Rare Autoimmune Disease

The U.S. FDA gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder in adults that express a specific biomarker.

Read More »

Exelixis’ Late-Stage Melanoma Combination Falls Short in Phase III Trial

Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.

Read More »

Merck to Acquire Tilos Therapeutics

Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.

Read More »

Experimental drug delays type 1 diabetes onset in mid-stage trial

In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

Read More »

Forty Seven Inc. and Acerta Enter Collaboration

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

Read More »

Study points to new antibody approach to tackling Ebola, other infections

Scientists working on developing vaccines against Ebola have found they can “harvest” antibodies from volunteers vaccinated in research trials and use them to make treatments for the deadly viral infection.

Read More »

Novartis and Blackstone Launch Anthos Therapeutics With $250 Million

Private investment firm Blackstone Life Sciences along with Novartis launched Anthos Therapeutics with a $250 million investment.

Read More »

Alder Submits BLA to U.S. FDA for Eptinezumab

Alder BioPharmaceuticals Inc. announced the submission of a Biologics License Application (BLA) to the U.S. FDA for eptinezumab for migraine prevention targeting the calcitonin gene-related peptide (CGRP).

Read More »

Prior dengue infection may protect against Zika: study

Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.

Read More »

Argenx and Halozyme Ink Multiple Target Deal

Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom